Global Home Global Home  
 
 

News

Date Title and Summary Additional Formats
Toggle Summary Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2018 Financial Results
Strong Annual Year-Over-Year Growth in Revenue of 30% $10 Million in Cash as of March 31, 2018 Conference Call Begins at 4:30pm EDT Today PETALUMA, Calif. , June 13, 2018 (GLOBE NEWSWIRE) --   Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a specialty pharmaceutical company that develops and markets
View HTML
Toggle Summary U.SK, dermatology arm of Brazilian NC Group, and Sonoma Pharmaceuticals Enter into License Agreement for Exclusive Rights to Sonoma’s Dermatology Products in Brazil
SAO PAULO, Brazil and PETALUMA, Calif. , June 05, 2018 (GLOBE NEWSWIRE) -- U.SK Dermatology, the dermatology arm of NC Group , which besides other businesses is the largest pharmaceutical organization in Brazil both in units sold and revenues, and Sonoma Pharmaceuticals, Inc.
View HTML
Toggle Summary Sonoma Pharmaceuticals Announces Fiscal Year/Fourth Quarter 2018 Financial Results and Conference Call
PETALUMA, Calif. , May 31, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), today announced that financial results for its fiscal fourth quarter 2018, ended March 31, 2018 , will be released after the U.S. markets close on June 13, 2018 .
View HTML
Toggle Summary Sonoma Pharmaceuticals Names Marc Umscheid Chief Operating Officer
PETALUMA, Calif. , May 08, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a specialty pharmaceutical company that develops and markets unique and effective dermatological solutions, announced today that Marc Umscheid has been promoted to chief operating officer effective
View HTML
Toggle Summary Sonoma Pharmaceuticals Receives Four New UAE Regulatory Approvals that Include Acne and Anti-Fungal Products
PETALUMA, Calif. , April 17, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today announced it
View HTML
Toggle Summary Sonoma Pharmaceuticals Announces FDA Approval for Antimicrobial Post-Therapy Gel
PETALUMA, Calif. , April 05, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for management of dermatological conditions and advanced tissue care, today announced it has
View HTML
Toggle Summary Sonoma Pharmaceuticals Introduces New and Improved Acuicyn™ Antimicrobial Eyelid and Eyelash Hygiene Solution
PETALUMA, Calif. , March 27, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of dermatological conditions and advanced tissue care, today launched a
View HTML
Toggle Summary Sonoma Pharmaceuticals to Present at Roth Capital Partners 30th Annual Growth Stock Conference on March 13, 2018
PETALUMA, Calif. , March 09, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA, Warrants - SNOAW) today announced that Jim Schutz , Sonoma CEO, will be a featured presenter at the Roth Capital Partners 30th Annual Growth Stock Conference on Tuesday, March 13, 2018 at 3:00 pm PDT in
View HTML
Toggle Summary Sonoma Pharmaceuticals Announces Closing of $5 Million Public Offering of Common Stock
PETALUMA, Calif. , March 06, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals , Inc. (Nasdaq: SNOA, Warrants - SNOAW) today announced the closing of a public offering of 1,428,570 shares of common stock at a public offering price of $3.50 per share. The net proceeds to Sonoma Pharmaceuticals, Inc.
View HTML
Toggle Summary Sonoma Pharmaceuticals Announces Pricing of $5 Million Public Offering of Common Stock
PETALUMA, Calif. , March 02, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, Warrants - SNOAW) today announced the pricing of a "best efforts" public offering of up to 1,428,571 shares of common stock at a public offering price of $3.50 per share.
View HTML